CLSA Lifts GenFleet Target to HK$61.9 on Cancer Drug Trial

Edgen Stock·Mar 26 2026, 04:46

Share to

Share to

Copy link

Key Takeaways

CLSA has increased its price target for GenFleet Therapeutics, citing better-than-expected financial performance and key advancements in its drug pipeline, particularly for its cancer treatments. The move reflects growing confidence in the company's development pathway as it successfully advances key assets through clinical trials.

Price Target Increased: CLSA lifted its price target for GenFleet (02595) to HK$61.9 from HK$60.8, maintaining an 'Outperform' rating on the stock.
Pipeline Progress: The upgrade follows news that GenFleet's pancreatic cancer drug, GFH375, has entered the registration trial phase, a critical step toward commercialization.
Financials Beat Estimates: The company reported 2025 revenue of RMB 1.3 billion, a 24.42% year-over-year increase, outperforming market expectations despite a wider net loss.

CLSA Raises GenFleet Target to HK$61.9 as Cancer Drug Advances

On March 26, investment bank CLSA raised its price target for GenFleet Therapeutics-B (02595) to HK$61.9 from HK$60.8, reaffirming its 'Outperform' rating. The upgrade was driven by significant progress in the company's clinical pipeline, most notably the advancement of its drug candidate GFH375 into registration trials for pancreatic cancer. This milestone is seen as a major de-risking event. In response, CLSA increased its profit forecasts for GenFleet by 4% for 2026 and 5.3% for 2027, signaling confidence in the company's long-term growth powered by its pan-RAS inhibitor, GFH276.

Revenues Grew 24.4% in 2025, Beating Market Forecasts

The positive analyst action was supported by GenFleet's 2025 financial results, which surpassed market expectations. The company generated RMB 1.3 billion in revenue, a 24.42% increase from the prior year. Management also demonstrated cost discipline, with research and development expenses declining by 15.01% to RMB 2.82 billion. Although GenFleet's net loss widened to RMB 17.95 billion, this figure was less severe than analysts had predicted, suggesting improving operational controls.

Clinical Milestones Drive Broader Biotech Valuations

CLSA's bullish stance on GenFleet reflects a wider market trend where investors are rewarding biotechnology firms for tangible clinical progress. The sector has seen a series of positive developments, including Denali Therapeutics securing accelerated FDA approval on March 25 for AVLAYAH™, a first-in-class treatment for Hunter syndrome. Furthermore, Novartis recently announced a $2 billion upfront deal to acquire a promising breast cancer asset. These events underscore an environment where progress in drug development is a primary catalyst for higher valuations and strategic M&A activity.